Creo Medical Group Future Growth
Future criteria checks 0/6
Creo Medical Group's revenue is forecast to decline at 4.9% per annum while its annual earnings are expected to grow at 41% per year. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be -14.7% in 3 years.
Key information
41.0%
Earnings growth rate
45.6%
EPS growth rate
Medical Equipment earnings growth | 14.2% |
Revenue growth rate | -4.9% |
Future return on equity | -14.7% |
Analyst coverage | Low |
Last updated | 24 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 28 | -11 | -14 | -13 | 2 |
12/31/2025 | 32 | -11 | -16 | -15 | 3 |
12/31/2024 | 34 | -19 | -2 | -16 | 3 |
6/30/2024 | 30 | -22 | -22 | -20 | N/A |
3/31/2024 | 31 | -22 | -22 | -21 | N/A |
12/31/2023 | 31 | -22 | -23 | -22 | N/A |
9/30/2023 | 30 | -23 | -24 | -22 | N/A |
6/30/2023 | 29 | -25 | -25 | -23 | N/A |
3/31/2023 | 28 | -26 | -27 | -24 | N/A |
12/31/2022 | 27 | -27 | -28 | -25 | N/A |
9/30/2022 | 27 | -28 | -33 | -27 | N/A |
6/30/2022 | 26 | -28 | -38 | -30 | N/A |
3/31/2022 | 26 | -26 | -35 | -28 | N/A |
12/31/2021 | 25 | -25 | -32 | -26 | N/A |
9/30/2021 | 24 | -23 | -26 | -22 | N/A |
6/30/2021 | 22 | -21 | -19 | -19 | N/A |
3/31/2021 | 16 | -21 | -18 | -18 | N/A |
12/31/2020 | 9 | -20 | -17 | -16 | N/A |
9/30/2020 | 5 | -19 | -17 | -16 | N/A |
6/30/2020 | 0 | -17 | -17 | -16 | N/A |
3/31/2020 | 0 | -17 | -15 | -14 | N/A |
12/31/2019 | 0 | -16 | -13 | -12 | N/A |
6/30/2019 | 0 | -13 | -14 | -13 | N/A |
3/31/2019 | 0 | -12 | -12 | -11 | N/A |
12/31/2018 | N/A | -10 | -10 | -10 | N/A |
12/31/2017 | 0 | -8 | N/A | -9 | N/A |
9/30/2017 | 0 | -8 | N/A | -8 | N/A |
6/30/2017 | N/A | -8 | N/A | -7 | N/A |
6/30/2016 | 1 | -5 | N/A | -5 | N/A |
2/29/2016 | 1 | -3 | N/A | -3 | N/A |
2/28/2015 | N/A | -2 | N/A | -2 | N/A |
2/28/2014 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1RC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1RC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1RC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1RC's revenue is expected to decline over the next 3 years (-4.9% per year).
High Growth Revenue: 1RC's revenue is forecast to decline over the next 3 years (-4.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1RC is forecast to be unprofitable in 3 years.